 - Closed merger with Neos Therapeutics creating a proforma combined 100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform PKCβ inhibitor, AR101 enzastaurin to development pipeline - - Record quarter for consumer health division with revenue reaching 8.4 million and Rx division revenue up 9 over same quarter last year - - Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET - ENGLEWOOD, CO ACCESSWIRE May 17, 2021 Aytu BioPharma, Inc. NASDAQ:AYTU, a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for the fiscal third quarter ended March 31, 2021 and provided recent business highlights. 